NYSE · ANRO
Healthcare · Biotechnology
$22.19
Up+$0.51 (+2.30%)
Updated Nov 3, 2026, 11:57 PM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ANRO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
ANRO closed at $22.19 after 21 trading sessions, down 7.58% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $22.80 | $23.18 | $21.495 | $22.19 | 473.28K |
| Oct 30, 2026 | $23.21 | $23.21 | $21.90 | $22.60 | 484.41K |
| Oct 29, 2026 | $23.46 | $24.15 | $22.92 | $23.47 | 388.83K |
| Oct 28, 2026 | $22.86 | $23.47 | $22.34 | $23.33 | 300.2K |
| Oct 27, 2026 | $22.22 | $23.35 | $21.90 | $23.19 | 469.26K |
| Oct 26, 2026 | $22.17 | $22.26 | $21.70 | $22.11 | 550.07K |
| Oct 23, 2026 | $21.95 | $22.45 | $21.45 | $21.97 | 379.25K |
| Oct 22, 2026 | $22.70 | $24.29 | $22.18 | $22.20 | 510.82K |
| Oct 21, 2026 | $24.74 | $25.01 | $23.28 | $23.32 | 663.46K |
| Oct 20, 2026 | $23.23 | $24.91 | $23.02 | $24.41 | 869.41K |
| Oct 19, 2026 | $22.36 | $23.40 | $22.01 | $22.82 | 681.86K |
| Oct 16, 2026 | $21.97 | $22.63 | $21.71 | $21.94 | 648.35K |
| Oct 15, 2026 | $21.92 | $23.31 | $21.62 | $22.62 | 529.86K |
| Oct 14, 2026 | $21.83 | $22.59 | $21.32 | $21.71 | 2.28M |
| Oct 13, 2026 | $24.04 | $24.20 | $22.07 | $22.09 | 663.33K |
| Oct 12, 2026 | $24.34 | $25.2533 | $23.855 | $24.15 | 390.27K |
| Oct 9, 2026 | $24.00 | $25.11 | $23.81 | $24.37 | 649.43K |
| Oct 8, 2026 | $23.03 | $24.045 | $22.81 | $24.03 | 409.79K |
| Oct 7, 2026 | $23.39 | $24.42 | $23.325 | $23.52 | 348.03K |
| Oct 6, 2026 | $24.06 | $24.70 | $23.50 | $23.69 | 576.59K |
| Oct 5, 2026 | $24.63 | $25.85 | $23.795 | $24.01 | 550.29K |
The latest Smart Investors Daily articles mentioning ANRO.
Company
Market Activity
Research & News
ANRO research
Company profile and research snapshot.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 17, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2026 | Wedbush | Neutral | — |
| Aug 13, 2026 | BTIG | Buy | — |
| May 18, 2026 | Baird | Outperform | — |
No generated briefing is available yet.
Benzinga · Oct 19, 2026
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alto Neuroscience (NYSE:ANRO) with a Buy and raises the price target from $55 to $60.
SeekingAlpha · Oct 15, 2026
Alto Neuroscience, Inc. pivots to ALTO-207 for treatment-resistant depression; learn risks, catalysts, dilution, and outlook. Click for this ANRO stock update.
Yahoo · Oct 13, 2026
Here is how Cardinal Health (CAH) and Alto Neuroscience, Inc. (ANRO) have performed compared to their sector so far this year.
Yahoo · Sep 9, 2026
MOUNTAIN VIEW, Calif., September 09, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ANRO.
